ABRA acts as an activator of serum response factor (SRF)-dependent transcription possibly by inducing nuclear translocation of MKL1 or MKL2 and through a mechanism requiring Rho-actin signaling (By similarity).
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.